14Nov
13Nov
Tech 50 2020: Honoring Pittsburgh’s Top Technology Companies
The Pittsburgh Technology Council's annual Tech 50 Awards honored technology innovation in the Pittsburgh region with a virtual gala event on Nov. 12, 2020. List includes CytoAgents CEO Teresa Whalen, RPh was selected as a finalist for Pittsburgh Technology Council's #TECH50 “CEO of the Year.” Read more >>
13Nov
Innovation Project Spotlight November 2020
A donor-independent, on-demand emergency source of platelets is needed to serve as a medical countermeasure (MCM) for mass casualty incidents. See how BARDA is investing in Platelet Biogenesis’s advanced manufacturing platform to develop synthetic platelet-like cells. Read more >>
13Nov
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:35 PM EST. Read more >>
12Nov
Feast or famine? Natural foods companies grapple with COVID realities
While everyone needs to eat — pandemic or no pandemic — and grocery stores have mostly thrived through the COVID-19 outbreak, the virus has created some unique challenges for the Boulder Valley region’s natural and organic product makers...“We’re trying to beat Clorox to those empty shelves,” 1908 Brands CEO Steve Savage said. 1908 is the parent company behind the Boulder Clean line of cleaning supplies. Read more >>
11Nov
Pitch your Side Hustle on Shark Tank | David Zamarin
David Zamarin was running a successful side business in high school. After selling that business, he created a liquid repellant company named Detrapel. His pitch on Shark Tank was so on point he landed a 6 figure deal. Watch now >>
11Nov
Neuraly Announces Strategic Sponsored Research Agreement with the University of Pennsylvania to Explore use of NLY01 to Therapeutically Target a Neuroinflammatory Mechanism of Glaucoma
Neuraly, Inc, a clinical-stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced a strategic sponsored research agreement with the University of Pennsylvania to study the use of NLY01 to therapeutically target a neuroinflammatory mechanism of glaucoma. Read more >>
10Nov
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today presented additional data from the RESOLVE-1 Phase 3 study of lenabasum for the treatment of systemic sclerosis. Read more >>
10Nov
eSight Opens First US Office, Bringing New Possibilities to People Living With Visual Impairments
Leading vision enhancement company, eSight, is expanding its global presence with the opening of its first office in the U.S. The Toronto-based company has chosen the Nashville, Tennessee area in order to better support its growing distribution network of low vision assistive technology specialists, retinal specialists, ophthalmologists, optometrists, and the agencies that work with members of the low vision community on a daily basis. Read more >>
06Nov